1.Fortin, PR, Lew, RA, Liang, MH et al. (1995) Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. J Clin Epidemiol 48, 1379–1390.
2.James, MJ & Cleland, LG (1997) Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum 27, 85–97.
3.Kremer, JM, Lawrence, DA, Petrillo, GF et al. (1995) Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Arthritis Rheum 38, 1107–1114.
4.Goldberg, RJ & Katz, J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129, 210–223.
5.MacLean, CH, Mojica, WA, Morton, SC et al. (2004) Effects of Omega-3 Fatty Acids on Lipids and Glycemic Control in Type II Diabetes and the Metabolic Syndrome and on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal Disease, Systemic Lupus Erythematosus, and Osteoporosis. Evidence Report/Technology Assessment. No. 89. Publication No. 04-E012-2. Rockville, MD: Agency for Healthcare Research and Quality.
6.Skoldstam, L, Borjesson, O, Kjallman, A et al. (1992) Effect of six months of fish oil supplementation in stable rheumatoid arthritis. A double blind, controlled study. Scand J Rheumatol 21, 178–185.
7.Belch, JJF, Ansell, D, Madhok, R et al. (1988) Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind controlled study. Ann Rheum Dis 47, 96–104.
8.Lau, CS, Morley, KD & Belch, JJ (1993) Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis – a double blind placebo controlled study. Br J Rheumatol 32, 982–989.
9.Kremer, JM, Lawrence, DA, Jubiz, W et al. (1990) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Arthritis Rheum 33, 810–820.
10.Lau, CS, McLaren, M & Belch, JJ (1995) Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis. Clin Exp Rheumatol 13, 87–90.
11.Nordstrom, DC, Honkanen, VE, Nasu, Y et al. (1995) Alpha-linolenic acid in the treatment of rheumatoid arthritis. A double-blind, placebo-controlled and randomized study: flaxseed vs. safflower seed. Rheumatol Int 14, 231–234.
12.Nielsen, GL, Faarvang, KL, Thomsen, BS et al. (1992) The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized double blind trial. Eur J Clin Invest 22, 687–691.
13.Van Doornum, S, McColl, G & Wicks, IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46, 862–873.
14.Maradit-Kremers, H, Crowson, CS, Nicola, PJ et al. (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52, 402–411.
15.John, H, Kitas, G, Toms, T et al. (2009) Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 23, 71–82.
16.Farkouh, ME & Greenberg, BP (2009) An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 103, 1227–1237.
17.Mozaffarian, D (2008) Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Clin Nutr 87, 1991S–1996S.
18.Albert, CM, Campos, H, Stampfer, MJ et al. (2002) Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346, 1113–1118.
19.GISSI Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447–455.
20.McLennan, PL, Bridle, TM, Abeywardena, MY et al. (1992) Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J 123, 1555–1561.
21.McLennan, PL (2001) Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 36, S111–S114.
22.Billman, GE, Kang, JX & Leaf, A (1999) Prevention of sudden cardiac death by dietary pure ν-3 polyunsaturated fatty acids in dogs. Circulation 99, 2452–2457.
23.Metcalf, RG, Sanders, P, James, MJ et al. (2008) Effect of dietary n-3 polyunsaturated fatty acids on the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am J Cardiol 101, 758–761.
24.Schrepf, R, Limmert, T, Claus Weber, P et al. (2004) Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet 363, 1441–1442.
25.Cleland, LG, Caughey, GE, James, MJ et al. (2006) Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J Rheumatol 33, 1973–1979.
26.Fries, JF, Murtagh, KN, Bennett, M et al. (2004) The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 50, 2433–2440.
27.Smith, CJ, Zhang, Y, Koboldt, CM et al. (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95, 13313–13318.
28.Hori, T, Oka, T, Hosoi, M et al. (1998) Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann NY Acad Sci 840, 269–281.
29.Engblom, D, Ek, M, Saha, S et al. (2002) Prostaglandins as inflammatory messengers across the blood-brain barrier. J Mol Med 80, 5–15.
30.Guay, J, Bateman, K, Gordon, R et al. (2004) Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 279, 24866–24872.
31.Chen, M, Lam, BK, Kanaoka, Y et al. (2006) Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 203, 837–842.
32.Lands, WE (1991) Biosynthesis of prostaglandins. Annu Rev Nutr 11, 41–60.
33.Hawkes, JS, James, MJ & Cleland, LG (1991) Separation and quantification of PGE3 following derivatization with panacyl bromide by high pressure liquid chromatography with fluorometric detection. Prostaglandins 42, 355–368.
34.Cleland, LG, James, MJ, Gibson, RA et al. (1990) Effect of dietary oils on the production of n-3 and n-6 metabolites of leukocyte 5-lipoxygenase in five rat strains. Biochim Biophys Acta 1043, 253–258.
35.Goldman, DW, Pickett, WC & Goetzl, EJ (1983) Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 117, 282–288.
36.Meydani, SN, Endres, S, Woods, MM et al. (1991) Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 121, 547–555.
37.Endres, S, Ghorbani, R, Kelley, VE et al. (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320, 265–271.
38.Caughey, GE, Mantzioris, E, Gibson, RA et al. (1996) The effect on human tumor necrosis factor α and interleukin-1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 63, 116–122.
39.Sijben, JWC & Calder, PC (2007) Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc Nutr Soc 66, 237–259.
40.Grimble, RF, Howell, WM, O'Reilly, G et al. (2002) The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr 76, 454–459.
41.James, MJ, Ursin, VM & Cleland, LG (2003) Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr 77, 1140–1145.
42.Serhan, CN, Chiang, N & Van Dyke, TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349–361.
43.Sun, Y-P, Oh, SF, Uddin, J et al. (2007) Resolvin D1 and Its Aspirin-triggered 17R Epimer: Stereochemical assignments, anti-inflamamatory properties, and enzymic inactivation. J Biol Chem 282, 9323–9334.
44.Serhan, CN, Hong, S, Gronert, K et al. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196, 1025–1037.
45.Arita, M, Bianchini, F, Aliberti, J et al. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201, 713–722.
46.Ishida, T, Yoshida, M, Arita, M et al. (2009) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 1, 1.
47.Kremer, JM, Bigauoette, J, Michalek, AV et al. (1985) Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1, 184–187.
48.Tulleken, JE, Limburg, PC, Muskiet, FAJ et al. (1990) Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. Arthritis Rheum 33, 1416–1419.
49.van der Tempel, H, Tulleken, JE, Limburg, PC et al. (1990) Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis 49, 76–80.
50.Volker, D, Fitzgerald, P, Major, G et al. (2000) Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 27, 2343–2346.
51.Kremer, JM, Jubiz, W, Michalek, A et al. (1987) Fish-oil fatty acid supplementation in active rheumatoid arthritis. Ann Intern Med 106, 497–503.
52.Cleland, LG, French, JK, Betts, WH et al. (1988) Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol 15, 1471–1475.
53.Kjeldsen-Kragh, J, Lund, JA, Riise, T et al. (1992) Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis. J Rheumatol 19, 1531–1536.
54.Geusens, P, Wouters, C, Nijs, J et al. (1994) Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. Arthritis Rheum 37, 824–829.
55.Wolfe, F & Hawley, DJ (1985) Remission in rheumatoid arthritis. J Rheumatol 12, 245–252.
56.O'Dell, JR, Leff, R, Paulsen, G et al. (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46, 1164–1170.
57.Egsmose, C, Lund, B, Borg, G et al. (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22, 2208–2213.
58.Cush, JJ (2007) Early rheumatoid arthritis – is there a window of opportunity? J Rheumatol 80, 1–7.
59.Maini, RN, Breedveld, FC, Kalden, JR et al. (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50, 1051–1065.
60.Moreland, LW, Schiff, MH, Baumgartner, SW et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130, 478–486.
61.Weinblatt, ME, Keystone, EC, Furst, DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48, 35–45.
62.James, M & Cleland, L (2008) COMET results are not stellar. Lancet 372, 1807–1808.
63.Proudman, SM, Keen, HI, Stamp, LK et al. (2007) Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 37, 99–111.
68.Keystone, EC, Kavanaugh, AF, Sharp, JT et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400–1411.